Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
Atossa Therapeutics, Inc. (ATOS)
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.atossagenetics.com
Company Research
Source: GlobeNewswire
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Ms. Rees brings almost 30-years of accounting, business and financial experience to the CFO role. She has spent the last seven years of her career at Atossa having joined the Company as Controller in 2017. Prior to joining Atossa, Ms. Rees led a consulting practice that delivered financial and accounting services to companies including Getty Images Inc., Flow International Corp, and Avalara, Inc. Earlier in her career she served as Controller of the Americas for Irdeto Inc. She began her career at
Show less
Read more
Impact Snapshot
Event Time:
ATOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATOS alerts
High impacting Atossa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATOS
News
- Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics updates protocol for breast cancer treatment trial [Yahoo! Finance]Yahoo! Finance
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerGlobeNewswire
- Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
ATOS
Sec Filings
- 7/2/24 - Form 8-K
- 7/1/24 - Form 4
- 7/1/24 - Form 4
- ATOS's page on the SEC website